The Increasingly Limited Basis for Portal Venous Pressure Modulation in Living Donor Liver Transplantation
Kambiz Etesami, Yuri Genyk – 27 September 2018
Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease
Erin E. Elbel, Joel E. Lavine, Michael Downes, Mark Van Natta, Ruth Yu, Jeffrey B. Schwimmer, Cynthia Behling, Elizabeth M. Brunt, James Tonascia, Ronald Evans – 27 September 2018 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adults. This study examined the relationship between hepatic nuclear receptor (NR) expression and histologic features of NAFLD. Drugs targeting a variety of NRs for nonalcoholic steatohepatitis (NASH) are in clinical trials.
Liver Transplantation in Adults With Liver Disease Due to Common Variable Immunodeficiency Leads to Early Recurrent Disease and Poor Outcome
Navneet Ramlaul, Jacob Ooi, Gary P. Jeffrey, Gerry MacQuillan, George Garas, Leon A. Adams, Masood Iqbal, Niamh Nolan, Diarmaid D. Houlihan, P. Aiden McCormick, Ross Mac Nicholas – 27 September 2018
Prohibitin 1 Acts As a Negative Regulator of Wingless/Integrated‐Beta‐Catenin Signaling in Murine Liver and Human Liver Cancer Cells
Nirmala Mavila, Yuanyuan Tang, Joshua Berlind, Komal Ramani, Jiaohong Wang, José M. Mato, Shelly C. Lu – 27 September 2018 – Prohibitin1 (PHB1) is a mitochondrial chaperone with diverse functions that include cell proliferation, apoptosis, and mitochondrial homoeostasis. Liver‐specific Phb1 knockout (KO) mice develop spontaneous injury and hepatocellular carcinoma (HCC). Our previous work demonstrated that PHB1 negatively regulates the H19‐insulin‐like growth factor 2 (IGF2)‐H19‐IGF2 axis signaling pathway and E‐box activity in hepatocytes and HCC cells.
Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease
Sander Lefere, Frederique Van de Velde, Anne Hoorens, Sarah Raevens, Sanne Van Campenhout, Astrid Vandierendonck, Sara Neyt, Bert Vandeghinste, Christian Vanhove, Charlotte Debbaut, Xavier Verhelst, Jo Van Dorpe, Christophe Van Steenkiste, Christophe Casteleyn, Bruno Lapauw, Hans Van Vlierberghe, Anja Geerts, Lindsey Devisscher – 26 September 2018 – Angiogenesis contributes to the development of nonalcoholic steatohepatitis (NASH) and promotes inflammation, fibrosis, and progression to hepatocellular carcinoma (HCC). Angiopoietin‐2 (Ang‐2) is a key regulator of angiogenesis.
Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
Anne S. Henkel, Sadiya S. Khan, Shantel Olivares, Toshio Miyata, Douglas E. Vaughan – 26 September 2018 – Plasminogen activator inhibitor 1 (PAI‐1), an essential regulator of fibrinolysis, is increasingly implicated in the pathogenesis of metabolic disorders, such as obesity and nonalcoholic fatty liver disease (NAFLD). Pharmacologic inhibition of PAI‐1 is emerging as a highly promising therapeutic strategy for obesity and its sequelae.
Reducing Posttransplant Readmissions: Tangible Solutions May Be Within Reach
Marina Serper – 26 September 2018
Simultaneous Liver and Kidney Transplantation: How to Expand the Kidney Donor Pool?
Kara Walter, Christopher K. Johnson, Lena Sibulesky – 26 September 2018
Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease
Rahima A. Bhanji, Praveena Narayanan, Michael R. Moynagh, Naoki Takahashi, Mounika Angirekula, Cassie C. Kennedy, Kristin C. Mara, Ross A. Dierkhising, Kymberly D. Watt – 26 September 2018 – Sarcopenia and frailty are commonly encountered in patients with end‐stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait‐list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated.
Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis
Christopher B. O’Brien, Eytan R. Barnea, Paul Martin, Cynthia Levy, Eden Sharabi, Kalyan R. Bhamidimarri, Eric Martin, Leopold Arosemena, Eugene R. Schiff – 26 September 2018 – Preimplantation factor (PIF) is an evolutionary conserved peptide secreted by viable embryos which promotes maternal tolerance without immune suppression. Synthetic PIF (sPIF) replicates native peptide activity. The aim of this study was to conduct the first‐in‐human trial of the safety, tolerability, and pharmacokinetics of sPIF in patients with autoimmune hepatitis (AIH).